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Abstract 
Circulating (CTC) and disseminated tumor cells (DTC) are two different steps in the metastatic 
process. Several recent techniques have allowed detection of these cells in patients, and have 
generated many results using different isolation techniques in small cohorts. Herein, we review 
the detection results and their clinical consequence in esophageal, gastric, pancreatic, colorectal, 
and liver carcinomas, and discuss their possible applications as new biomarkers. 
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1. Introduction 
Onset of metastasis is a complex yet poorly understood process, which is responsible for most of 
cancer-related deaths. For several years, cellular dissemination from primary to secondary sites 
has been a “black-box” of research for clinicians. In non-metastatic (M0) patients, clinical studies 
have isolated strong prognostic factors associated with the risk of metastatic relapse, and these 
factors are being used to make decisions on adjuvant treatments. Adjuvant chemotherapy targets 
cancer cells that may have disseminated throughout the body, but is currently given blinded to the 
real dissemination status of each patient. With continuous technical improvements, detection 
methods have been recently set up and validated to isolate cancer cells in the blood (circulating 
tumor cells (CTC)) and in the bone marrow (disseminated tumor cells (DTC)). The opening of 
these two windows on the metastatic process in patients has raised three main critical issues: Are 
detection methods accurate? Is quantitative analysis (i.e., counts) of CTCs/DTCs of clinical 
relevance? Could qualitative analysis (i.e., molecular characterization) of CTCs/DTCs uncover 
new cancer features/targets? This review focuses on results obtained by different CTC/DTC 
detection methods in gastro-intestinal cancers. 
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2. Technical aspects 
2.1 CTC and DTC detection sites 
Metastasis is a complex multistep process, which emerged as a biological and clinical research 
field more than a century ago. In one of the first studies to investigate the metastatic spread of 
breast cancer, James Paget made the well-known “seed and soil” hypothesis to explain the 
discrepancy between the blood supply of the different organs and the distribution of breast-cancer 
metastases[1]. Since this seminal report, several steps in the hematogeneous metastatic process 
have been described: local invasion, intravasation into blood vessels, interaction with blood-
formed elements, arrest on the vessel’s endothelium, extravasation, invasion of the host-organ 
microenvironment, cellular dormancy, and establishment of a new growth. 
Basically, CTC corresponds to the circulation step of cancer cells, after intravasation, 
whereas DTC corresponds to the post-extravasation steps. Noteworthy, CTCs are generally 
detected in the peripheral blood, which is supposed to have a homogeneous cancer-cell 
concentration, but many gastrointestinal (GI) studies have also looked for CTC in the efferent vein 
of primary GI tumors, i.e., the portal vein. As looking for DTCs in solid organs is technically 
difficult, DTCs are almost exclusively detected in bone marrow (by a sternum or iliac-crest 
puncture). These different detection sites have to be kept in mind, especially in GI cancers, in 
which the liver may act as a physical blood-filter for CTCs released by the primary tumor. Finally, 
cancer cells are not definitely set into one of these “compartments”: cellular trafficking between 
the primary tumor site, the blood, the bone-marrow, other target-organs, and metastases are very 
likely, as has been reported in a few pre-clinical [2] or clinical [3] models. 
 
2.2 CTC and DTC detection methods 
In a few solid tumors that exhibit specific gene-fusion transcripts (e.g., EWS/FLI1 in Ewing’s 
sarcoma), DTC/CTC detection has already been clinically implemented as a strong prognostic 
marker for use in everyday clinics, either at diagnosis or after the primary treatment, and is often 
called a “minimal residual disease”. However, since the first CTC description in the late 19
th
 
century [4], as most carcinomas do not have specific transcripts, DTC and CTC have been 
detected using different techniques, leading to successive results that can appear heterogeneous 
[5,6]. These techniques generally consist of isolating cells with epithelial markers out of 
mesenchymal-derived compartments (blood, bone marrow) [7]; two steps are generally used: 
primary enrichment, followed by DTC/CTC detection.  
Almost every isolation technique relies on an initial CTC/DTC-enrichment step, generally 
based on positive immunoselection of cells expressing an epithelial membranous marker, such as 
epithelial-cell adhesion (EpCAM, MUC1…). Other enrichment techniques have been also 
reported: size-based differential filtering (ISET), CD45-based leukocyte-negative 
immunoselection… None of these techniques have a 100% yield for CTC/DTC purification, and 
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the use of multiple-antigen selection (by combining different antibodies) has not yet demonstrated 
clear superiority over single-antigen selection. Moreover, high discrepancy rates can be observed 
using different antibodies against the same membranous marker, as is shown in colorectal cancer 
[8]. This preliminary step, which could be followed by either molecular or cytological detection 
techniques, is highly heterogeneous among techniques, and is critical to understanding 
discrepancies between published studies in the same setting. 
Molecular detection of CTC/DTC relies on the detection of mRNA (by RT-(q)PCR, mRNA 
hybridization onto cDNA membrane…), which is related either to epithelial function or to specific 
cancer hallmarks, such as telomerase activity. Target mRNA (CEA, MUC1, cytokeratins…), and 
primers used for the amplification step are heterogeneous among studies, which are generally 
monocentric. For example, in the recent meta-analysis by Rahbari et al [6],  on CTC/DTC 
detection in colorectal cancer, more than 20 different targets were assessed, alone or in 
combination, in 31 molecular studies conducted in more than 25 different single centers. 
However, the specificity of these molecular techniques is questioned, as nonspecific expression 
of epithelial markers has been reported in lymphoid cells activated by cancer-related systemic 
inflammation [9]. 
Cytological detection of CTC/DTC, after the initial enrichment step, relies on 
immunostaining of CTC/DTC, using epithelial antigens thought to be expressed by carcinoma 
cells (e.g., epithelial cytokeratins). Multiple staining can be performed on isolated cells, generally 
by immunocytofluorescence. The standardized CellSearch® system [10], which has become the 
most commonly used CTC detection system over the past few years, enriches the sample (7.5 ml 
of blood) cells that express the EpCAM molecule, with antibody-coated magnetic beads, and 
labels the cells with a fluorescent nucleic acid dye (DAPI). Fluorescently labeled monoclonal 
antibodies specific for leukocytes (CD45-allophycocyan) and epithelial cells (cytokeratin 8, 18, 19-
phycoerythrin) are used to distinguish epithelial cells from leukocytes. Beyond epithelial-staining, 
cytological detection methods allow the optical control of stained cells [11], in order to distinguish 
cancer cells from activated lymphoid cells. This final validation step of cell morphology is time-
consuming, hardly automatable, and relies on expert cytologists and/or technicians who should 
use a standardized classification consensus [12] whenever available. Our review is mainly 
focused on the clinical applications of cytology-based CTC/DTC-detection techniques, which are 
more homogeneous and have, at least for the CellSearch® system, the advantage of 
demonstrated reproducibility across centers and studies [13,14]. 
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3 Esophageal cancers 
3.1 DTCs 
Although bone and bone marrow are not preferential sites for macrometastasis of esophageal 
cancer, DTCs have been primarily found in 37% of 90 non-metastatic patients after an iliac-crest 
puncture using a cytological technique based on cytokeratin detection [15]. DTCs were 
associated, in this study, with poor survival in patients with completely excised tumors. 
Interestingly, bone-marrow DTCs were more frequently detected (79%) when extracted from a rib 
contiguous to the tumor than from the iliac crest (8%), but rib-derived DTCs had no clear 
prognostic significance [16,17]. Biologically, whole-genome analysis of single DTCs isolated by 
micropipetting in 107 patients showed that most genetic aberrations were different in primary 
tumors and in bone marrow DTCs [18], supporting the parallel-evolution model, proposed for 
metastatic processes, by CA Klein [19]. In this study, gain of the HER2 gene region on 17q was 
the most common genomic alteration shared between DTCs, and was associated with shorter 
overall survival. 
 
3.2 CTCs 
CTC detection in esophageal cancers has been mainly reported by molecular techniques in 
patients undergoing surgery with a curative intent. These studies have focused mainly on CEA 
mRNA expression [20-24], but also on CK19, CK20 [25,26], SCC [27], deltaNp63 [28],  and 
survivin [29,30]. Detection rates are heterogeneous among studies, even when the same mRNA 
has been quantified in the same clinical setting, e.g., 77% [29] vs. 47% [30] for survivin, 57% [21] 
vs. 28% [22] for CEA. Almost all of these exploratory studies show a negative prognostic impact 
of CTC detection on survival, although these reports are on small heterogeneous cohorts. 
Reports based on CTC cytological detection are even more limited; a negative prognostic impact 
and a correlation with pleural dissemination were found in 5 patients out of 23 metastatic 
esophageal-cancer patients who had ≥2 CTCs/7.5 ml of blood, as assessed with the CellSearch® 
system [31,32]. 
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4. Gastric adenocarcinoma 
4.1 DTCs 
Bone marrow DTCs have been reported by several detection techniques in surgically resected 
gastric cancers: CK18 [33]; CK2-immunostaining [34]; anti-human epithelial antigen (Ber-EP4) 
[35]; CK20 RT-PCR [36], CK20/CK19/CEA RT-PCR [37], CK7/CK8 RT-PCR [38], 
CEA/CK20/TFF1/MUC2 RT-PCR [39]. About half of these studies reported a significant negative 
prognostic impact on metastases-free and/or overall survival. DTC detection has been associated 
with increased tumor-microvessel density [40,41]; its association with VEGFR expression by the 
primary tumor appears controversial [42]. As not every single DTC will later grow into a 
macrometastase, a German group developed further investigations into DTCs isolated by a 
cytological technique. They showed that immunostaining of proteins involved in the urokinase 
plasminogen-activator (uPA) system may distinguish those that have a fully metastatic phenotype 
and an independent clinical impact [43-45]. Recently, they also reported that the extracellular 
matrix-metalloprotease inducer (EMMPRIN) may also play a role in DTCs’ evolution to later 
macrometastases [46].  
 
4.2 CTCs 
CTCs in gastric cancer have been studied in several small studies, reported in Table 1. No clear 
conclusion can be drawn from these heterogeneous studies, which are often underpowered. 
Among the several molecular markers tested (CK18, 19, 20, CEA, hTERT (human telomerase 
reverse transcriptase)), none has demonstrated a clear and confirmed superiority over the others 
[47-51]. CTC-detection rate was related to the surgical maneuvers during the surgical removal of 
excisable cancers, and was initially correlated with poor survival [52]. This CTC release was 
confirmed in another study (n=59), though CTC-positivity after surgery was surprisingly 
associated with an improved prognosis [53]. A few reports have also focused on the patient’s 
blood stored for autologous transfusion during surgery, by testing CTSs using various techniques 
after removal from blood by freezing, filtering, and irradiation [54,55]. Decreases in CTC have 
been also reported in about half of patients receiving neoadjuvant chemotherapy [56]. Biological, 
preclinical experiments suggest a strong role for CTC arrest in premetastatic niches of target 
organs, characterized by VEGFR1-positive bone-marrow-derived non-tumoral cells [57]. To date, 
gastric adenocarcinoma is the only cancer in which the impact of VEGFR1-positive non-tumoral 
cells has been demonstrated in the presence of CTC, as was reported in 810 Japanese patients 
[58]. 
  Using the CellSearch® system, CTC detection rates were 14% and 55% in 14 non-
metastatic and 27 metastatic patients, respectively (≥2 CTCs/7.5ml) [32]. Recently a Japanese 
group has reported an association between CTC detection and chemotherapy efficacy in 52 
metastatic gastric-cancer patients treated with different chemotherapy regimens in advanced 
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metastatic disease [59]. As for other cancer types, high CTC count under treatment (here, ≥4 
CTCs/7.5 ml at 2–4 weeks after the start of the treatment) was associated with a poorer outcome 
(progression-free survival (PFS): 1.4 vs. 4.9 months; overall survival (OS): 3.5 . 11.7 months). 
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5. Pancreatic cancer 
In the metastatic setting, the CTC detection rate, using the CellSearch® system, has been 
recently investigated in four small cohorts (n=16 [10]; n=23 [60]; n=14 [61]; n=40 [62]): CTCs 
were detected in ~50% of patients (≥1 CTC/7.5 ml), but the mean count appears lower than in 
colorectal cancers. Although underpowered, three of these studies addressed the prognostic 
significance of CTC detection and reported contradictory results (two being rather positive, one 
rather negative). Using a microfluidic device for CTC sorting (immunoselection and staining being 
similar to CellSearch®), a group at Massachusetts General Hospital recently reported 100% CTC 
detection in 15 metastatic pancreatic-cancer patients [63]. However, this detection rate may be 
overestimated, similar to their prostate cancer results [64]. In 2001, a study from the same 
hospital reported 105 patients with stage I–IV pancreatic cancer with 26% CTC and 28% DTC 
detection rates (AE1/AE3 immunostaining)[65]. Both CTC and DTC detection rates were 
correlated with disease stage and were not prognostic in multivariate analysis. Similarly, an older 
cytological study (using a cocktail of six antibodies) [66] and two molecular-technique-based 
studies (CK20 and CEA) [67,68] retrieved an association between DTC and/or CTC detection and 
disease stage; multivariate analyses of survival were either not reported or were inconclusive  
In locally advanced pancreatic cancers, which are unresectable but are still not 
metastatic, CTC/DTC may indicate how far the dissemination process is advanced, and could 
guide the physician’s choice towards a local (e.g., radiotherapy) or systemic (chemotherapy) 
treatment. No significant data have been published yet in this setting, but a French companion 
study of the LAP07 trial (NCT00634725) is currently ongoing, using the CellSearch® system. 
In early pancreatic cancer, detection rates are likely to be low with the current cytological 
techniques. Bone-marrow DTC detection by multiple antibodies has been, however, associated 
with a shorter time to tumor relapse in 15 patients who underwent complete surgical resection 
[69]. For CTC detection, a single case report has been published using the CellSearch® system 
for diagnostic purposes in a patient presenting with a pancreatic mass [70], which found 4 
CTCs/7.5 ml, whereas the mass turned out to be a pancreatic carcinoma. However, in this 
diagnostic setting, both sensitivity and specificity of this technique are too low to fulfill the 
requirements of a diagnostic test. Molecular techniques have been also tested in this setting [71-
73], but their specificity have been discussed when they are used as a single marker, especially 
for CK20 [74].  
Finally, pancreatic and ileal neuroendocrine tumors (NET) strongly express EpCAM, and 
CTC detection by the CellSearch® system was only reported in one study reported to date: 43% 
of patients with metastatic ileal NET (n=26) and 21% of patients with metastatic pancreatic NET 
(n=16) [75]. CTC detection was associated with tumor progression in this study. 
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6. Colorectal adenocarcinoma: the adjuvant setting 
6.1 DTCs 
 
The first large study to show an association between DTC detection and worse prognosis in non-
metastatic colorectal cancer patients (n=88) was reported almost 20 years ago [76]. Adjuvant 
trials that tested the anti-EpCAM monoclonal antibody, edrecolomab, were launched on the 
bases that most bone-marrow DTCs express EpCAM [77] and that tumor response or 
stabilization has been observed in metastatic patients in Phase-2 studies [78]. However, adjuvant 
Phase-3 trials with edrecolomab have shown no clinical benefit [79,80]. Other reports on DTC 
detection were included in a large meta-analysis published recently (see after 6.2) [6]. Liver DTCs 
were studied in liver biopsies using molecular techniques, but had no clear clinical impact on 
resected colorectal cancers [81]. 
 
6.2 CTCs 
Many studies have been conducted, by different surgical teams, at the time of resecting primary 
colon tumors. Many have looked for CTCs during surgery in the portal flow, using molecular or 
cytological [82] techniques, in order to measure circulating tumor load. The focus on portal flow is 
based on the hypothesis that the portal vein represents a “post-intravasation highway” for CTCs 
from the primary tumor to the liver, which is the main target organ for the metastatic process in 
colon cancer. Some studies have also focused on the potential release of CTCs into the portal 
vein during different surgical procedures using various vascular clamps or “no-touch” techniques 
[83-85]. Also, in patients diagnosed with an occlusive colorectal cancer, a small study (n=58) 
suggested that endoscopic insertion of a colonic stent resulted in increased levels of CK20 
mRNA, compared to staging colonoscopy [86]. Clearance of CTC after surgery has been reported 
to be a quick event in most patients, possibly associated with the prognosis [87]. A decrease in 
CTC was also reported after neoadjuvant chemoradiation for rectal cancers [88]. Some other 
studies have focused on the potential filter role of the liver on CTC dissemination, and compared 
CTCs in synchronous samples obtained from the portal vein, sus-hepatic veins, and/or the 
peripheral blood [89].  
Globally, cytological techniques, including the CellSearch® technique, have reported very 
low detection rates in stage II and III colon cancers [90]. With molecular techniques, the different 
published results were reported as heterogeneous, especially for CTC prognostic impact [91], 
and no clear conclusion could be drawn. Therefore, a first meta-analysis was published in 2008 
based of nine studies that used molecular detection (646 patients) [92]. Two interesting 
conclusions were reported: (i) CTC detection in the portal flow is correlated with nodal invasion 
(21% of pN0 patients vs. 50% of pN+ patients); and (ii) CTC status at the time of surgery is 
correlated with disease-free survival and to further liver metastatic relapse, independently of 
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tumor stage (I, II, or III). One of the largest studies in stage II patients (n=194) was published 
almost synchronously, and reported detection of CTCs in peripheral blood using four mRNAs 
(CEA, hTERT, CK19, CK20) [93]. In this pilot study, the combination of tumor-invasion depth, 
vascular invasion, and mRNA markers as predictors of relapse, showed that patients with any 
one positive predictor had a hazard ratio, of about 27-fold, of developing a postoperative relapse 
(p<0.001). This result has not been confirmed, but may be of critical importance when selecting 
stage II cancer patients who may benefit from adjuvant chemotherapy. 
A larger meta-analysis has been published recently, which included 36 studies that 
reported on the detection of DTCs in bone-marrow, on CTCs in the portal vein, and systemic 
circulation of CTCs, using several molecular and cytological techniques in 3094 patients with non-
metastatic colorectal cancers [6]. When pooled together, cancer-cell detection studies were 
significantly associated with shorter recurrence-free intervals and overall survival rates. When 
they looked separately at different sampling sites, only peripheral blood CTCs had a prognostic 
value, whereas bone-marrow DTCs or portal-vein CTCs were not significantly associated with 
overall survival. 
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7. Colorectal adenocarcinoma: the metastatic setting 
7.1 DTCs 
Bone-marrow DTC detection in the metastatic setting has been reported only in small studies 
[94,95], and has no clear prognostic significance. This is consistent with similar findings for 
metastatic breast cancer [96]. 
7.2 CTCs 
CTCs have been also detected by cytological or molecular techniques in this setting. Several 
small studies have been published on molecular techniques, using the same markers as already 
discussed, alone or in combination with CEA, CK 8/18/19/20, hTERT, MUC1/2... Interestingly, 
detection of K-RAS mutations has been also investigated [97-99], as have p53 mutations 
[97,99,100]. Here, again, no molecular marker demonstrated superiority in these small studies. 
In metastatic colorectal cancers, surgical teams have focused on patients with resectable 
liver metastases. In this specific setting, detection of CTCs may reflect an active hematogeneous 
dissemination process and, therefore, may help to distinguish patients who can experience a 
short progression-free interval after surgery from those who can have longer complete remission 
[67,101]. Similar concerns for gastric cancers have been raised regarding autologous blood-
transfusion safety during hepatic surgery [54]. CTC release during radiofrequency ablation of liver 
metastases was also reported to be higher than during surgical resection [102]. A randomized 
clinical trial has been proposed to compare two surgical procedures for CTC detection during 
surgery as the primary endpoint [103]. 
 For chemotherapy management, some reports with limited patient numbers, have 
suggested that variations in CTC counts may be associated with treatment response [104]. For 
this application, the cytological CellSearch® technique has achieved very strong evidence, with 
several studies published on metastatic colorectal cancers (Table 2). Based on the study reported 
by Cohen et al. [105], the CellSearch® system gained, in 2007, FDA approval as an aid to 
monitor metastatic colorectal-cancer patients. This study reported the strong and independent 
prognostic impact of CTC-positivity (≥3CTC/7.5ml) at baseline, but also of early CTC changes 
after 3–5 weeks of treatment (chemotherapy with or without bevacizumab). In a large ancillary 
study to the CAIRO2 trial (chemotherapy + bevacizumab, with or without cetuximab), Tol et al 
[106] reported similar findings at baseline, but a lower CTC-positivity rate after 3–5 weeks of 
treatment (Table 2). 
The correlation with outcome must, therefore, have been inconclusive, and the CTC count after 
1–3 weeks of treatment was analyzed instead of its correlation with treatment outcome. 
The discrepancy between these studies may be due to the systematic use of 
bevacizumab in the second trial, which has been reported in breast cancer to lower the CTC-
detection rate [107]. Without further research, it is unclear when to perform a CTC count after the 
start of treatment (i.e., weeks 1–2 vs. weeks 3–5) to detect the best correlation with outcome. 
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Moreover, these observational studies have focused on patients with good health and have not 
demonstrated that “managing treatment” according to CTC-count leads to a better outcome. 
Interventional randomized trials are therefore needed to compare the standard 
clinical/radiological vs. quantitative CTC-guided management of metastatic colorectal-cancer 
patients. Moreover, CTC positivity under treatment corresponds to cancers that are 
spontaneously resistant to a first-line regimen, and there is no evidence to support the idea that 
introducing a second-line regimen, according to the CTC count under treatment or to radiological 
evaluation, which occurs 1–2 months later, will help improve the survival of these refractory 
patients. 
Therefore, it is likely that the main management of chemotherapy according to 
quantitative CTC changes will be the earlier discontinuation of expensive, harmful, and worthless 
treatments for some patients, and a gain in the cost/effectiveness ratio, rather than an 
improvement in survival. CTC may be also of interest to patients with potentially resectable liver 
metastases, i.e., metastases that may be surgically removed if metastasis shrinkage is obtained. 
These patients usually received intensive polychemotherapy combined with a targeted therapy, 
and CTC might help to select those patients who will most benefit from this treatment strategy. As 
an example, Figure 1 shows the design of the CTC companion-study in a recently started large 
multicenter trial. 
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8. Hepatocarcinoma (HCC) 
Non-metastatic hepatocarcinomas are treated whenever possible by local treatments, which may 
include liver resection, liver allograft, chemoembolization, and alcoholization. Beyond the issue of 
a possible surgery-induced CTC release [108], any metastasis-associated biomarker could be 
clinically relevant, as most patients relapse after treatment of the primary tumor. Following initial 
studies, which have reported that AFP mRNA detection in blood was associated with disease 
stage [109,110], several CTC molecular-detection studies have been published (Table 3): 
heterogeneous clinical results were reported, whereas AFP mRNA specificity was discussed 
[111,112]. DTC detection by the same marker has been also reported in small studies [113]. 
Albumin, human telomerase (hTERT), and melanoma antigen gene-1 (MAGE1) mRNAs detection 
were also investigated, in blood, in a few small studies [114-117]. 
Cytological detection methods have also been used in HCC. The ISET technique, which 
isolates CTC by size on a filter, has been primarily developed in HCC [118]. In 44 non-metastatic 
HCC patients, CTC-detection rate was about 50% and was associated with shorter survival [119]. 
Similar detection rates (45%) were reported more recently with the CellSearch® system in 20 
patients (≥1 CTCs/7.5ml), but these patients either had metastatic or locally advanced HCC [120]. 
Finally, circulating CD45
–
/CD90
+
 cells, described as HCC “stem cells”, have been found by flow-
cytometry in 31 out of 34 (90%) non-metastatic HCC patients, but the correlation with clinical 
outcome was not reported [121]. 
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9. Conclusion 
Globally, molecular tools used for CTC and DTC detection, based on their epithelial phenotype, 
are very heterogeneous, and it is hazardous to assess their importance based of them being a 
small series. Most of the reports in the literature had positive results (i.e., association with 
outcome), but publication bias may seriously distort any attempts, including those of the 
published meta-analyses, to estimate the effect of CTC/DTC detection. One may hypothesize that 
molecular techniques were mostly developed by isolated academic teams, without any strong 
effort to standardize these techniques. Cytological-detection studies were initially academy-
driven, and gave interesting insights into the dissemination process and the genetic evolution 
from the primary tumor, to DTCs, to overt macrometastasis. This technical heterogeneity among 
these studies has paved the way for the development of the semi-automated and standardized 
CellSearch® system, with its development also benefiting large industry-sponsored clinical 
studies. This system became the 2011 gold standard for CTC detection, and is currently used in 
exploratory studies for several GI cancer types. The FDA-cleared quantitative approach to 
manage the chemotherapy of metastatic colorectal cancers is, however, not fully validated, and 
its clinical interest remains unknown. As recalled in a recent methodological review [122], the 
validation of CTC changes, as a recognized surrogate end-point for PFS will require data that 
demonstrate that CTC-changes are prognostic of PFS, but also that the effect of treatment on 
CTC-changes correlate with that of PFS; this will require the accumulation of data into a large 
meta-analysis. 
 The future of DTC and CTC in gastrointestinal cancers could be divided into two main 
issues. First, the quantitative count obtained by cytological techniques, such as CellSearch®, will 
be compared to several promising new blood-derived biomarkers, such as circulating tumor DNA 
or circulating miRNA. However, the future of CTCs as a quantitative biomarker appears somehow 
compromised by the detection of cancer-specific mutations (e.g., K-RAS mutations) in the blood. 
The second issue is that CTC may represent, in the near future, a kind of “liquid biopsy”, and 
provide new insights into tumor biology. The qualitative analysis of CTCs may guide treatment 
choice at diagnosis, but may also be repeated under treatment to elucidate resistance pathways, 
without an invasive tumor biopsy. CTCs may become a useful marker to assess many tumor 
targets by multiple immunostaining, FISH, and/or single-cell RNA/DNA analysis.  
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Table 1: CTC detection by molecular techniques in gastric adenocarcinoma 
Studies with ≤20 patients or without an outcome analysis were not included. Impact on survival was not systematically assessed in multivariate 
analysis. N/A: not available or not relevant (because M0 and M1 patients were pooled). NS: not significant. DMFS: distant metastasis-free survival; 
DFS: disease-free survival; OS: overall survival. 
 
Reference Patients Amplified mRNA CTC detection rate Clinical significance 
Soeth, 1997 [123] 
N= 30 
Stages I–IV 
CK20 17% N/A 
Yeh,1998 [48] 
N=34 
Stage IV 
CK19 21% OS : NS 
Noh, 1999 [20] 
N=35 
Stages I–IV 
CEA 
M+ : 100% 
All M- cancer : 33% 
Resectable cancer : 18%  
N/A 
Nishida[124] 
N=36 
Resectable cancer 
CEA 22% N/A 
Majima, 2000 
[125] 
N=52 
Stages I–IV 
CK19 and CK20 10% N/A 
Miyazono, [52] 
N=57 
Resectable cancer 
CEA 
- In portal vein, superior vena cava, and 
the peripheral artery 
- Before and after surgical removal 
 
37% 
- DMFS  
- Detection rate were similar at the different blood-
puncture sites 
- Surgical maneuvers may cause CTC release. 
Obayashi, 2001 
[54] 
N=25 
Resectable liver metastasis 
(include also colorectal cancer 
patients) 
CEA 
- Made on patient blood drawn for 
autologous transfusion during liver 
surgery 
20% 
CEA mRNA is no longer detectable after being 
frozen for 7 days 
Sumikura, 2003 
[126] 
N=106 
Resectable cancer 
CEA 40% 
DFS (non-hematogeneous metastases were 
included) 
 17 
Seo 2005 [127] 
N=46 
Resectable cancer 
CEA 
- at the time of surgery and then every 2 
months 
48% 
Changes after surgery and during follow-up are 
correlated with DFS 
 
Illert 2005 [128] 
N=70 
Stage I-III 
CK20 40% OS 
Uen, 2006 [129] 
N=52 
Stage I–-IV 
MUC1 
c-Met 
71% 
62% 
N/A 
Wu,2006 [130] 
N=64 
Stage I–IV 
CK19 
CEA 
MUC1 
hTERT 
4 markers combined : 
Sensitivity: 89% 
Specificity: 91% 
N/A 
Koga, 2008 [131] 
N=101 
Stage I–IV 
CK19 
CK20 
In operable patients 
12% 
15% 
OS 
Yie, 2008 [132] N=55 Survivin 44% DFS 
Saad 2010 [133] 
N=30 
resectable 
CK18  
- DFS 
- association with E-cadherin expression in the 
primary tumor 
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Table 2: CTC detection in colorectal cancer using the CellSearch® system 
 
Reference Patients 
CTC detection rate 
(threshold) 
Clinical significance 
Allard, 2004 
[10]  
N=196 
Stage IV 
Stage IV: 30% 
Threshold ≥2CTC/7.5ml 
N/A 
Cohen, 2006 
[134] 
N=50 
Stage IV 
Stage IV: 38% 
Threshold ≥2CTC/7.5ml 
- CTC positivity was associated with disease 
status (progression vs. non-progression). 
Sastre, 2008 
[135] 
Maestro 2009 
[136] 
N= 94 
Stage I–IV 
Stage II : 21% 
Stage III: 24% 
Stage IV: 61% 
Threshold ≥2CTC/7.5ml 
 
Cohen 2008 
[105] 
Cohen 2009 
[137] 
N=430 
Stage IV 
Stage IV : 
33% before treatment 
12% at week 3-5 
Threshold ≥3CTC/7.5ml 
- CTC positivity at baseline was independently 
associated with worse PFS (5 vs. 8 months) and 
OS (9 vs. 18 months). 
- Among initially CTC positive patients, those 
who become CTC negative at weeks 3–5 had a 
better PFS (6 vs. 2 months). 
Hiraiwa 2008 
[32] 
N=40 
Stage I-III: 18% 
Stage IV: 41% 
Threshold ≥2CTC/7.5ml 
- CTC positivity was not associated with outcome 
in the 29 stage-IV patients 
Jiao 2009 [102] 
N=29, with 
surgically resected 
liver metastases 
N/A 
7.5ml of blood analyzed at 
different sites (peripheral, portal 
and hepatic veins) 
- Surgical resection immediately reduced the 
number of CTCs compared with radiofrequency 
ablation, which was associated with an 
increased number of CTCs 
- Liver and lungs act as filters for CTCs 
Tol 2010 [106] N=467 
Stage IV: 
29% before treatment 
5% at week 3-5 
Threshold ≥3CTC/7.5ml 
- CTC positivity at baseline was associated with 
worse PFS (8 vs. 10.5 months) and OS (14 vs. 
22 months). 
- Among initially positive patients, those who 
became CTC negative at weeks 1–2 had a better 
PFS (8 vs. 4 months) 
Papavasiliou  
2010 [138] 
N=20, with 
surgically resected 
liver metastases 
Preoperative :10% 
Peroperative: 50% 
Postoperative:5% 
Threshold ≥3CTC/30ml 
Postoperative CTC detection was associated 
with DMFS and OS. 
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Table 3: Molecular detection of AFP mRNA in hepatocarcinoma (HCC) 
Studies with ≤20 patients or without an outcome analysis were not included. Impact on survival was not 
systematically assessed in multivariate analysis. 
Periph. Cath: peripheral catheter; Centr. Cath: central catheter 
N/A: not available 
DMFS: distant metastasis-free survival; DFS: disease-free survival; OS: overall survival. 
 
Reference 
Number 
of HCC 
patients 
Blood-puncture location 
and timing  
CTC detection rate Clinical significance 
Louha M,1997 
[139] 
84 
Periph. Cath. 
Before alcoholization?? 
or embolization therapy 
33% DMFS 
Matsumura 
M,1999 [140] 
88 
Periph. Cath. 
Before alcoholization or 
embolization therapy 
62% DMFS and OS 
Wong IH,1999 
[115] + 2000 
[141] 
 
62 
Periph. Cath. 
Before, during, and after 
surgery 
25% of samples DMFS 
Kienle P, 2000 
[113] 
24 
Centr. Cath. 
Before, during, and after 
surgery 
29–45% of patients 
(time-dependent) 
No significance 
Miyamoto A, 
2001 [142] 
23 
N/A 
Before, during, and after 
surgery 
25% of samples DFS 
Witzigmann H, 
2002 [143] 
85 
Periph Cath 
Before, during, and after 
surgical or palliative 
treatment  
28%  
No significance  
for surgery-treated patients 
Gross-Goupil M, 
2003 [144] 
52 
Before and after 
embolization therapy 
24% No significance 
Cillo U, 2004 
[112] 
40 
Periph. Cath. 
Before surgery 
40% DFS and OS 
Jeng KS, 2004 
[145,146] 
81 
Periph. Cath. 
12 weeks after surgery 
23% DFS 
Morimoto O,  
2005 [147] 
38 
Periph. Cath. 
Before surgery 
24% DMFS and DFS 
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Figure 1: CirCe 03, an ancillary study to the Prodige14-METHEPII-ACCORD21 trial 
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